StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$955.47+4.28 (+0.45%)

Close on Nov 13, 2026Market cap $98.84BP/E 21.1Yield –

Regeneron Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Regeneron Pharmaceuticals's price to book ratio was 3.2× on Nov 11, 2026, against 2.8× a year earlier. Over the last 5 years it ranged from 1.9× to 4.8×, with a median of 3.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.2×+0.5
2025Dec 31, 20252.7×−0.0
2024Dec 31, 20242.8×−1.2
2023Dec 29, 20234.0×+0.2
2022Dec 30, 20223.8×−0.3
2021Dec 31, 20214.1×−1.4
2020Dec 31, 20205.5×+1.4
2019Dec 31, 20194.1×−1.4
2018Dec 31, 20185.5×−1.7
2017Dec 29, 20177.2×−2.2
2016Dec 30, 20169.4×−9.5
2015Dec 31, 201518.9×+1.2
2014Dec 31, 201417.7×−1.4
2013Dec 31, 201319.1×−0.9
2012Dec 31, 201220.0×+8.3
2011Dec 30, 201111.7×+4.2
2010Dec 31, 20107.5×–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?